No Data
Strategy special report: Huitianfu A shares, Hong Kong stocks, US stock biotechnology index product investment value analysis: new industries, high-tech, long track
Jun Jun Biotechnology (00660-HK) issued 67 million yuan of stock exchange bonds at a premium to offset the loan
[Caihua News] Lu Jun Biotechnology (00660-HK) announced that it proposes to issue 3-year convertible bonds with a capital amount of 67 million yuan to an independent third party, Huang Zhiyong, with an annual interest rate of 4%; the exchange price is 0.022 yuan, a 4.76% premium over yesterday's closing price; convertible new shares account for 15.51% of the expanded share capital. The subscription amount will offset the outstanding principal amount and accrued interest on the loan payable by the Company to the subscriber. The board of directors believes that this loan with an interest rate of 6.25% per annum is a heavy financial burden for the Group because the company was at the level of net current liabilities on December 31, 2019, and now
Biotech company "Gaomei Gene" received tens of millions of yuan in Pre-A round financing
36Kr Holdings learned that Gaomei Gene, a biotechnology company for early detection of cancer, recently received tens of millions of yuan in Pre-A round financing, invested by high-tech venture capital under Nanjing Jiangbei New area Science and Technology Investment Group. The financing funds will be mainly used to accelerate the listing of liver cancer early detection products and the registration of liver cancer early screening IVD products; at the same time, improve the database of multi-cancer early detection, and continue to promote the research and development of early detection technology for digestive system tumors and gynecological tumors.
Pfizer and German biotech company BioNTech plan to produce up to 100 million doses of COVID-19 vaccine by the end of 2020
Pfizer and German biotech company BioNTech plan to produce up to 100 million doses of COVID-19 vaccine by the end of 2020
Meikang Biotech (300439.SZ): Subsidiary obtains medical device registration certificate
Glonhui, July 27丨Meikang Biology (300439.SZ) announced that Ningbo Meikang Shengde Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained the “People's Republic of China Medical Device Registration Certificate” issued by the Zhejiang Drug Administration. The product name is a fully automated glycated hemoglobin analyzer. The scope of application is used for quantitative detection of glycated hemoglobin in blood. Ningbo Meikang Shengde Biotechnology Co., Ltd.'s acquisition of the “Registration Certificate” for the liquid chromatography analysis instrument mentioned above has further enriched and improved the variety of the company's product line, better met the diversified needs of the market, and is conducive to improving the public sector
Biotech industry: the trend of sublingual desensitization is trending, and the publication of the first desensitization guide favors medium- to long-term development
The prevalence of allergic diseases is increasing year by year, and the desensitizing drug market is vast. The prevalence of allergic diseases in China is gradually increasing, driving the rapid expansion of the allergy medicine market. Judging from the sales of drugs for allergic diseases in sample hospitals in key cities across the country in 2019, antihistamines still occupy about 83% of the market space. Desensitization treatment is the only method recommended by WHO that may change the natural course of allergic diseases. Relevant drugs account for only about 16%, and there is still a lot of room for improvement in penetration rate. The global desensitization market has an oligopoly pattern, with leading companies focusing on developing sublingual desensitization products. Global desensitization treatment market